Eli Lilly & Co. Lilly announces agreement to acquire prevail therapeutics. December 15, 2020. https://investor.lilly.com/news-releases/news-release-details/lilly-announces-agreement-acquire-prevail-therapeutics (last accessed December18, 2020).
2.
FrangoulH, AltshulerD, CappelliniMD, et al.CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med [Epub ahead of print]; DOI: 10.1056/NEJMoa2031054
3.
CRISPR Therapeutics and Vertex. CRISPR therapeutics and vertex present new data for investigational CRISPR/Cas9 Gene-Editing Therapy, X001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine. December 5, 2020. http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-present-new-data-investigational (last accessed December21, 2020).
4.
Bayer. Bayer establishes cell and gene therapy platform to accelerate pharmaceutical innovation. December 2, 2020. https://media.bayer.com/baynews/baynews.nsf/id/Bayer-establishes-Cell-and-Gene-Therapy-Platform-to-accelerate-pharmaceutical-innovation (last accessed December19, 2020).
5.
PassageBio. PassageBio announces gene therapy manufacturing research and development site. December 16, 2020. https://investors.passagebio.com/news-releases/news-release-details/passage-bio-announces-gene-therapy-manufacturing-research-and (last accessed December18, 2020).
6.
Neurogene. Neurogene closes $115 million series B financing. December 16, 2020. https://www.neurogene.com/press-releases/neurogene-closes-115-million-series-b-financing (last accessed December19, 2020).
Thermo Fisher Scientific. Thermo fisher expands clinical and commercial capabilities for plasmid DNA manufacturing. December 16, 2010. https://thermofisher.mediaroom.com/2020-12-16-Thermo-Fisher-Expands-Clinical-and-Commercial-Capabilities-for-Plasmid-DNA-Manufacturing (last accessed December19, 2020).
9.
Janssen Pharmaceuticals. Janssen acquires rights to novel gene therapy, pioneering treatment solutions for late-stage age-related macular degeneration. December 2, 2020. https://www.janssen.com/janssen-acquires-rights-novel-gene-therapy-pioneering-treatment-solutions-late-stage-age-related (last accessed December19, 2020).
10.
Atsena Therapeutics. Atsena Therapeutics raises $55 million series A financing to advance LCA1 gene therapy clinical program, two preclinical assets, and novel capsid development for ocular diseases. December 16, 2020. https://atsenatx.com/press-release/atsena-therapeutics-raises-55-million-series-a-financing-to-advance-lca1-gene-therapy-clinical-program-two-preclinical-assets-and-novel-capsid-development-for-ocular-diseases (last accessed December19, 2020).
